fluoroestradiol
Trade name: Cerianna
Small moleculeapprovedImaging agent
Approved
May 20, 2020
Fluoroestradiol F-18, also known as [18F]16α-fluoroestradiol and sold under the brand name Cerianna, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging. It is an analog of estrogen and is used to detect estrogen receptor-positive breast cancer lesions. — Wikipedia
Clinical trial activity
30 trials · 25 clinical orgs · 2 marketing orgs
Phase 1
5
Phase 2
15
Phase 3
2
Phase 4
1
Earliest trial started Sep 1, 2008 (NCT00602043)
Timeline
Indications
Approved for
Mechanism of action
- Estrogen receptorBINDING AGENT
ESR1 binding agent
- Unspecified targetOTHER
Diagnostic agent
Diagnostic agent. Binds ER in ER-positive human breast cancers allowing PET imaging.
Approval history
- approvedMay 20, 2020
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](F)[C@@H]2O- Mol. weight
- 290.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 18-fluorine
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaFluoroestradiol (18F) ↗
- ChEMBLCHEMBL4594261 ↗
- ChEMBLCHEMBL1627367 ↗
- WikipediaFluoroestradiol F-18 ↗
Also known as
- 18f 16 alpha-fluoroestradiol
- 18f fes
- 18f fes
- 18f fluoroestradiol
- 6alpha-[18f]fluoro-17beta-estradiol
- 6α-[18f]fluoro-17β-estradiol
- f-18 16 alpha-fluoroestradiol
- f-18 fes
- fluorestradiol
- fluoroestradiol
- fluoroestradiol
- fluoroestradiol f-18
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07112053 | Phase 2 | Nov 24, 2025 | University of Washington |
| NCT06260033 | Phase 2 | Jul 23, 2024 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05916196 | Phase 2 | Sep 1, 2023 | University of Pennsylvania |
| NCT05486182 | Phase 4 | Feb 8, 2022 | General Electric, Keosys, Simbec-Orion, Zionexa |
| NCT04692103 | Phase 2 | Jul 10, 2021 | University of Washington |
| NCT04727632 | Early Phase 1 (Phase 1) | Apr 28, 2021 | University of Utah |
| NCT04347135 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2020 | Mayo Clinic |
| NCT04252859 | Early Phase 1 (Phase 1) | Jun 30, 2020 | University of Utah |
| NCT04382911 | Phase 2 | Jun 1, 2020 | University of North Carolina at Chapel Hill |
| NCT03873428 | N/A | May 31, 2019 | Centre Georges Francois Leclerc |
| NCT03619044 | N/A | Sep 30, 2018 | University of Toulouse |
| NCT03544762 | Phase 3 | Sep 8, 2017 | National Taiwan University |
| NCT03065712 | Phase 2 | Feb 22, 2017 | The University of Texas, Dallas |
| NCT02806050 | Phase 2 | Sep 1, 2016 | University of Groningen |
| NCT02899533 | Phase 1 | Jul 1, 2016 | University of Pennsylvania |
| NCT02398773 | Phase 2 | Feb 2, 2016 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT03507088 | N/A | Sep 1, 2015 | Fudan University |
| NCT02559544 | N/A | May 1, 2015 | University of Pennsylvania |
| NCT02374931 | N/A | Apr 1, 2015 | National Cancer Institute (NCI), Vanderbilt University |
| NCT01988324 | Phase 2 | Aug 31, 2014 | University of Groningen |
Showing 20 of 30 trials
Page 1 / 2
Organizations
Research & Development (25)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 2 | 2 | 2008 |
| University of Washington | Academic/Hospital | 5 | 5 | 2 | 2010 |
| University of Pennsylvania | Academic/Hospital | 4 | 3 | 3 | 2008 |
| University of Groningen | Academic/Hospital | 3 | 3 | 1 | 2011 |
| University of Utah | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Centre Georges Francois Leclerc | Academic/Hospital | 1 | 1 | 1 | 2019 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| General Electric | For profit | 1 | 0 | 1 | 2022 |
| Keosys | For profit | 1 | 0 | 1 | 2022 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Taiwan University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Simbec-Orion | For profit | 1 | 0 | 1 | 2022 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Angers | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2012 |
25 organizations
Page 1 / 2
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| General Electric | For profit | MKTG | May 20, 2020 |
| Zionexa | For profit | MKTG | May 20, 2020 |
| Zionexa | For profit | SYN | May 20, 2020 |
| Zionexa | For profit | NDA2 | May 20, 2020 |
| Zionexa | For profit | NDA | May 20, 2020 |